Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2024 10:16 ET | Source: NodThera

NodThera Named a ‘Fierce 15’ Company by Fierce Biotech

NodThera Named a ‘Fierce 15’ Company by Fierce Biotech Philadelphia, PA, August 5, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic...
June 12, 2024 07:00 ET | Source: NodThera

NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk

NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk ...
February 19, 2024 07:00 ET | Source: NodThera

NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors

NodThera Ltd (“NodThera” or the “Company”) NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors ...
February 05, 2024 07:00 ET | Source: NodThera

NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer

Se NodThera Ltd (“NodThera” or the “Company”) NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage...
July 11, 2023 07:00 ET | Source: NodThera

NodThera is first to demonstrate reduction in neuroinflammation in the clinic with brain penetrant NLRP3 inflammasome inhibitor

NodThera Ltd (“NodThera” or the “Company”) NodThera is first to demonstrate reduction in neuroinflammation in the clinic with brain penetrant NLRP3 inflammasome inhibitor NT-0796 demonstrates...
June 20, 2023 07:00 ET | Source: NodThera

NodThera announces positive first-in-human data for two brain penetrant NLRP3 inflammasome inhibitors

NodThera Ltd (“NodThera” or the “Company”) NodThera announces positive first-in-human data for two brain penetrant NLRP3 inflammasome inhibitors Oral, small molecule, clinical candidates NT-0249...